[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552265":3},{"organization":4,"outcomesModule":7,"designInfo":23,"detailedDescription":29,"studyPopulation":22,"armGroups":30,"interventions":37,"overallOfficials":44,"centralContacts":48,"locations":53,"responsibleParty":71,"collaborators":22,"id":74,"slug":22,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":22,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":22,"enrollmentInfo":82,"targetDuration":22,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":22,"overallStatus":91,"whyStopped":22,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Navy General Hospital, Beijing","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":22},[9],{"measure":10,"description":11,"timeFrame":12},"Overall Response Rate (ORR)","ORR was defined as the proportion of patients who achieved CR or PR as their best response","1 year",[14,18],{"measure":15,"description":16,"timeFrame":17},"Overall Survival (OS)","OS was defined as time from diagnosis to death from any cause or the last follow-up","through study completion, an average of 3 years",{"measure":19,"description":20,"timeFrame":21},"Progression Free Survival (PFS)","For patients in morphologic remission, documented relapse was considered progression. Relapse following complete remission(CR) is defined as reappearance of leukemic blasts in the peripheral blood or the finding of more than 5% blasts in the BM, not attributable to another cause (eg, BM regeneration after consolidation therapy) or extramedullary relapse.","2 years",null,{"allocation":24,"interventionModel":25,"interventionModelDescription":22,"primaryPurpose":26,"observationalModel":22,"timePerspective":22,"maskingInfo":27},"NA","SINGLE_GROUP","TREATMENT",{"masking":28,"maskingDescription":22,"whoMasked":22},"NONE","The investigators will evaluate response rate of CHG regimen Combined With Venetoclax in newly diagnosed acute myeloid leukemia. After induction therapy, patients will be given standardized treatment according to risk stratification according to NCCN guidelines. Progression free survival (PFS), Overall survival (OS), and Toxicity will be counted.",[31],{"label":32,"type":33,"description":34,"interventionNames":35},"CHG Combined With Venetoclax and Azacytidine","EXPERIMENTAL","Patients were treated by CHG Combined With Venetoclax and Azacytidine",[36],"Drug: CHG Combined With Venetoclax and Azacytidine",[38],{"type":39,"name":32,"description":40,"armGroupLabels":41,"otherNames":42},"DRUG","Patients were treated by CHG Combined With Venetoclax and Azacytidine:\n\nVenetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg\u002Fm2 subcutaneous injection qd d1-7; Homoharringtonine 1mg\u002Fm2 iv qd d1-14; Cytarabine 10mg\u002Fm2 subcutaneous injection q12h d1-14; G 250ug\u002Fm2 subcutaneous injection qd d0-14.",[32],[43],"VACHG",[45],{"name":46,"affiliation":5,"role":47},"Liren Qian, PhD","PRINCIPAL_INVESTIGATOR",[49],{"name":46,"role":50,"phone":51,"phoneExt":22,"email":52},"CONTACT","+861066947192","qlr2007@126.com",[54],{"facility":55,"status":22,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Navy General Hospital","Beijing","Beijing Municipality","100048","China","CN",{"type":62,"coordinates":63},"Point",[64,65],116.39723,39.9075,{"lat":65,"lon":64},[68],{"name":69,"role":50,"phone":70,"phoneExt":22,"email":52},"Liren Qian, M.D.","+861066957676",{"type":47,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":22,"oldOrganization":22},"Liren Qian","Vice Director","100552265",false,"NCT06470841","CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML","CHG Regimen Combined With Venetoclax and Azacytidine in Newly Diagnosed Acute Myeloid Leukemia","Inclusion Criteria:\n\n* The patient should, in the investigator's opinion, be able to meet all clinical trial requirements.\n* The patient is willing and able to adhere to the study visit schedule and other protocol requirements.\n* The patient should be diagnosed with AML according to the standard criteria of the World Health Organisation (WHO).\n* The patient should not have received any prior treatment for AML.\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women.","ALL","18 Years",{"count":83,"type":84},85,"ESTIMATED","INTERVENTIONAL",[87],"PHASE2","The goal of this phase 2 trial is to test the safety and efficacy of CHG Combined With Venetoclax in treating patients with newly diagnosed AML.",[90],"Acute Myeloid Leukemia","NOT_YET_RECRUITING","2024-08-21",{"date":94,"type":95},"2024-08-22","ACTUAL",{"date":97,"type":84},"2024-09-20",{"date":99,"type":84},"2028-12",{"name":5,"class":6},1]